We are live on ! Find out more
EW icon

Edwards Lifesciences

428 hedge funds and large institutions have $8.09B invested in Edwards Lifesciences in 2014 Q2 according to their latest regulatory filings, with 67 funds opening new positions, 96 increasing their positions, 177 reducing their positions, and 45 closing their positions.

New
Increased
Maintained
Reduced
Closed

49% more first-time investments, than exits

New positions opened: 67 | Existing positions closed: 45

12% more capital invested

Capital invested by funds: $7.25B → $8.09B (+$838M)

5% more funds holding

Funds holding: 409428 (+19)

9% more call options, than puts

Call options by funds: $44.5M | Put options by funds: $40.9M

0% more funds holding in top 10

Funds holding in top 10: 55 (0)

11.23% less ownership

Funds ownership: 547.24%536.01% (-11%)

46% less repeat investments, than reductions

Existing positions increased: 96 | Existing positions reduced: 177

Holders
428
Holders Change
+19
Holders Change %
+4.65%
% of All Funds
12.3%
Holding in Top 10
5
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.14%
New
67
Increased
96
Reduced
177
Closed
45
Calls
$44.5M
Puts
$40.9M
Net Calls
+$3.57M
Net Calls Change
-$6.18M
Name Holding Trade Value Shares
Change
Change in
Stake
BNP Paribas Financial Markets
151
BNP Paribas Financial Markets
France
$3.28M -$413K -30,492 -12%
HCM
152
Highbridge Capital Management
New York
$3.27M +$3.1M +228,468 New
DCC
153
Dow Chemical Company
Michigan
$3.26M
TSU
154
TD Securities (USA)
New York
$3.17M +$137K +10,122 +5%
Ameriprise
155
Ameriprise
Minnesota
$3.16M -$22.9K -1,686 -0.8%
KAH
156
Kathryn A. Hall
$3.09M +$2.93M +215,892 New
Stifel Financial
157
Stifel Financial
Missouri
$3.04M -$986K -72,738 -26%
AAM
158
Aberdeen Asset Management
United Kingdom
$3.01M +$1.88M +138,678 +194%
RPAM
159
Rhenman & Partners Asset Management
Sweden
$3M -$910K -67,122 -24%
Korea Investment Corp
160
Korea Investment Corp
South Korea
$2.98M +$2.82M +208,200 New
EWM
161
Endurance Wealth Management
Rhode Island
$2.95M +$2.8M +206,514 New
AAM
162
Autus Asset Management
Arizona
$2.92M +$16.7K +1,230 +0.6%
Nisa Investment Advisors
163
Nisa Investment Advisors
Missouri
$2.92M
NFA
164
Nationwide Fund Advisors
Ohio
$2.85M -$248K -18,312 -8%
SRC
165
Stone Run Capital
New York
$2.85M -$81.3K -6,000 -3%
RJA
166
Raymond James & Associates
Florida
$2.85M +$368K +27,156 +16%
USAA
167
United Services Automobile Association
Texas
$2.78M +$309K +22,800 +13%
US Bancorp
168
US Bancorp
Minnesota
$2.78M -$74.5K -5,496 -3%
GIBU
169
Gulf International Bank (UK)
United Kingdom
$2.56M
FAF
170
Fjarde Ap-fonden
Sweden
$2.56M -$195K -14,352 -7%
PP
171
Paloma Partners
Connecticut
$2.53M +$1.72M +126,840 +255%
MSA
172
Mason Street Advisors
Wisconsin
$2.52M -$117K -8,628 -5%
ACI
173
AMP Capital Investors
Australia
$2.51M +$97.6K +7,200 +4%
ASRS
174
Arizona State Retirement System
Arizona
$2.45M -$163K -12,000 -7%
Public Employees Retirement Association of Colorado
175
Public Employees Retirement Association of Colorado
Colorado
$2.42M -$117K -8,616 -5%

EW Hedge Fund Activity: Q2 2014 in Review

428 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Edwards Lifesciences (EW) for Q2 2014, worth a combined $8.09B — up 12% from $7.25B a quarter earlier.

Buyers outnumbered sellers: 67 funds opened new EW positions and 45 closed out — a net gain of 22 holders — while 96 added to existing stakes and 177 trimmed.

The largest buyer was Generation Investment Management, adding an estimated $153M. The largest seller was Capital Research Global Investors, cutting an estimated $203M.

  • 428 institutional investors held Edwards Lifesciences (EW) as of Q2 2014, up from 409 in Q1 2014.
  • Funds reported $8.09B of Edwards Lifesciences stock for Q2 2014, up 12% quarter-over-quarter.
  • 67 funds opened new Edwards Lifesciences positions in Q2 2014 and 45 closed out, a net change of +22 holders.
  • The largest Edwards Lifesciences buyer in Q2 2014 was Generation Investment Management, an estimated $153M added.
  • The largest Edwards Lifesciences seller in Q2 2014 was Capital Research Global Investors, an estimated $203M sold.

Based on aggregated 13F filings for Q2 2014.